Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Debt-to-Equity or its related term are showing as below:
RVPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.55 Med: -0.01 Max: 0.56
Current: 0.01
During the past 7 years, the highest Debt-to-Equity Ratio of Reviva Pharmaceuticals Holdings was 0.56. The lowest was -0.55. And the median was -0.01.
RVPH's Debt-to-Equity is ranked better than 99.9% of 970
companies
in the Biotechnology industry
Industry Median: 0.15
vs RVPH: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Reviva Pharmaceuticals Holdings Debt-to-Equity Related Terms
Reviva Pharmaceuticals Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVPH vs CVKD, ACXP, KAPA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reviva Pharmaceuticals Holdings (RVPH) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Reviva Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1 out of 970 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Reviva Pharmaceuticals Holdings' Debt-to-Equity too high?
Reviva Pharmaceuticals Holdings' current Debt-to-Equity is 0.01. The Biotechnology industry median Debt-to-Equity is 0.15. Reviva Pharmaceuticals Holdings' value of 0.01 is 93.3% below this industry median. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #1 out of 970 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Debt-to-Equity compare to CVKD and ACXP?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1 out of 970 companies for Debt-to-Equity. This places Reviva Pharmaceuticals Holdings in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.15. Reviva Pharmaceuticals Holdings' value of 0.01 is 93.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reviva Pharmaceuticals Holdings's current Debt-to-Equity of 0.01 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Reviva Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reviva Pharmaceuticals Holdings's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 93.3% below the Biotechnology industry median of 0.15. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score
Get the complete analysis for RVPH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 
